Е. В. Попова

813 total citations
77 papers, 333 citations indexed

About

Е. В. Попова is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Е. В. Попова has authored 77 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pathology and Forensic Medicine, 15 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Е. В. Попова's work include Multiple Sclerosis Research Studies (47 papers), Systemic Sclerosis and Related Diseases (9 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Е. В. Попова is often cited by papers focused on Multiple Sclerosis Research Studies (47 papers), Systemic Sclerosis and Related Diseases (9 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Е. В. Попова collaborates with scholars based in Russia, United States and Ukraine. Е. В. Попова's co-authors include И. С. Киселев, О. Г. Кулакова, О. О. Фаворова, Natalia Baulina, Alexey Boyко, Daniela Capsa, Jennifer Eriksson, Ludmila Danilova, Мarsel R. Kabilov and Valentin V. Vlassov and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Е. В. Попова

65 papers receiving 325 citations

Peers

Е. В. Попова
Agnieszka Karczmarczyk Poland
Thaidy Moreno-Rodriguez Spain
Serena Fineschi Italy
Gina M. Kavanagh United Kingdom
Shiori Kinoshita Japan
Junyi Pang China
Tina Nilsson Sweden
Jürgen Groet United Kingdom
Chad P. Soupir United States
Darryl Nousome United States
Agnieszka Karczmarczyk Poland
Е. В. Попова
Citations per year, relative to Е. В. Попова Е. В. Попова (= 1×) peers Agnieszka Karczmarczyk

Countries citing papers authored by Е. В. Попова

Since Specialization
Citations

This map shows the geographic impact of Е. В. Попова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Е. В. Попова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Е. В. Попова more than expected).

Fields of papers citing papers by Е. В. Попова

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Е. В. Попова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Е. В. Попова. The network helps show where Е. В. Попова may publish in the future.

Co-authorship network of co-authors of Е. В. Попова

This figure shows the co-authorship network connecting the top 25 collaborators of Е. В. Попова. A scholar is included among the top collaborators of Е. В. Попова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Е. В. Попова. Е. В. Попова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Попова, Е. В., et al.. (2024). Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion. Meditsinskiy sovet = Medical Council. 101–107.
2.
Попова, Е. В., et al.. (2024). Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab. Meditsinskiy sovet = Medical Council. 108–112.
3.
Попова, Е. В., et al.. (2023). Gut microbiota in patients with relapsing-remitting multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 123(1). 8–8. 1 indexed citations
4.
Попова, Е. В., et al.. (2023). Clinical markers for unfavorable course of multiple sclerosis. SHILAP Revista de lepidopterología. 17(3). 41–48.
5.
6.
Gilyazova, I. R., А. А. Измайлов, Marina Bermisheva, et al.. (2022). Germline mutations as possible biomarkers of immune checkpoint inhibitor therapy efficacy in patients with renal cell carcinoma (mini review). Open Access Repository (Belgorod State National Research University). 2 indexed citations
7.
Захарова, М. Н., et al.. (2022). New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»). S S Korsakov Journal of Neurology and Psychiatry. 122(7). 84–84. 3 indexed citations
8.
Попова, Е. В., et al.. (2021). Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases. SHILAP Revista de lepidopterología. 108–111. 1 indexed citations
9.
Попова, Е. В.. (2021). Clinical case of COVID-19 in a patient treated with alemtuzumab. SHILAP Revista de lepidopterología. 148–152. 1 indexed citations
10.
Попова, Е. В., et al.. (2020). The experience of using ocrelizumab in routine practice. SHILAP Revista de lepidopterología. 76–80.
11.
Попова, Е. В., et al.. (2020). New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire. S S Korsakov Journal of Neurology and Psychiatry. 120(7). 43–43. 4 indexed citations
12.
Evdoshenko, E. P., Е. В. Попова, С А Сиверцева, et al.. (2019). Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS ONE. 14(5). e0217303–e0217303. 6 indexed citations
13.
Evdoshenko, E. P., N A Malkova, Odinak Mm, et al.. (2019). The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 119(10). 110–110.
14.
Киселев, И. С., О. Г. Кулакова, Natalia Baulina, et al.. (2019). Вариабельность гена MIR196A2 как фактор риска развития первично-прогрессирующего рассеянного склероза. Молекулярная биология. 53(2). 282–289. 3 indexed citations
15.
Киселев, И. С., Natalia Baulina, Е. В. Попова, et al.. (2019). Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Multiple Sclerosis and Related Disorders. 29. 130–136. 20 indexed citations
16.
Попова, Е. В., et al.. (2017). The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy. S S Korsakov Journal of Neurology and Psychiatry. 117(10). 48–48. 4 indexed citations
17.
Попова, Е. В., et al.. (2016). Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 116(10. Vyp. 2). 68–68. 3 indexed citations
18.
Бойко, А. Н., et al.. (2015). Effect of pregnancy on the course of multiple sclerosis. SHILAP Revista de lepidopterología.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Agnieszka Karczmarczyk Breakdown of academic impact, for papers by Thaidy Moreno-Rodriguez Breakdown of academic impact, for papers by Serena Fineschi Breakdown of academic impact, for papers by Gina M. Kavanagh Breakdown of academic impact, for papers by Shiori Kinoshita Breakdown of academic impact, for papers by Junyi Pang Breakdown of academic impact, for papers by Tina Nilsson Breakdown of academic impact, for papers by Jürgen Groet Breakdown of academic impact, for papers by Chad P. Soupir Breakdown of academic impact, for papers by Darryl Nousome
Rankless by CCL
2026